Skip to content

Study · Case report or series · n = 1 · 2025

13 results

Rebound Effect Following the Discontinuation of Palopegteriparatide.

Naciu AM, Sargentini E, Tsourdi E, Palermo A, Tabacco G

Calcified tissue international16 Sept 2025

PMID40956444 (opens in a new tab)DOI10.1007/s00223-025-01432-3 (opens in a new tab)PepBankPUB-40956444
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a man restarted calcitriol at double his pre-palopegteriparatide dose.

    In plain wordsAfter palopegteriparatide discontinuation, a man restarted calcitriol at double his pre-palopegteriparatide dose.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseCalcitriol regimen at discontinuation
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    and restarted calcium and calcitriol therapy at different regimens (25% reduction in calcium and double dose of calcitriol compared to the respective doses before starting palopegteriparatide).
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  2. 02HumanCase report or seriesSafety outcome

    In a man with hypoparathyroidism, calcium remained stable one week after palopegteriparatide discontinuation with resumed conventional therapy.

    In plain wordsIn a man with hypoparathyroidism, calcium remained stable one week after palopegteriparatide discontinuation with resumed conventional therapy.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableCalcium one week after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    One week post-discontinuation, his calcium and phosphorus remained stable.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  3. 03HumanCase report or seriesSafety outcome

    In a man with hypoparathyroidism, phosphorus remained stable one week after palopegteriparatide discontinuation with resumed conventional therapy.

    In plain wordsIn a man with hypoparathyroidism, phosphorus remained stable one week after palopegteriparatide discontinuation with resumed conventional therapy.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicablePhosphorus one week after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    One week post-discontinuation, his calcium and phosphorus remained stable.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  4. 04HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a man developed symptomatic hypocalcemia one month later, with albumin-adjusted calcium 7.4 mg/dL.

    In plain wordsAfter palopegteriparatide discontinuation, a man developed symptomatic low calcium one month later, with calcium 7.4 mg/dL.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseSymptomatic hypocalcemia after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Measurements

    albumin-adjusted serum calcium
    7.4 mg/dL
    one month after palopegteriparatide discontinuation, symptomatic hypocalcemia

    Source sentences

    Summary
    However, one month later, he developed symptomatic hypocalcemia (albumin-adjusted serum calcium 7.4 mg/dL and phosphorus 5.1 mg/dL), requiring increased oral calcium doses to restore calcium levels to target ranges.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  5. 05HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a man had phosphorus 5.1 mg/dL when symptomatic hypocalcemia developed one month later.

    In plain wordsAfter palopegteriparatide discontinuation, a man had phosphorus 5.1 mg/dL when symptomatic low calcium developed one month later.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicablePhosphorus with hypocalcemia after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Measurements

    serum phosphorus
    5.1 mg/dL
    one month after palopegteriparatide discontinuation, with symptomatic hypocalcemia

    Source sentences

    Summary
    However, one month later, he developed symptomatic hypocalcemia (albumin-adjusted serum calcium 7.4 mg/dL and phosphorus 5.1 mg/dL), requiring increased oral calcium doses to restore calcium levels to target ranges.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  6. 06HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a man required increased oral calcium doses to restore target calcium during symptomatic hypocalcemia.

    In plain wordsAfter palopegteriparatide discontinuation, a man required increased oral calcium doses to restore target calcium during symptomatic low calcium.

    Peptide
    Palopegteriparatide
    Outcome
    IncreaseIncreased calcium requirement after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    However, one month later, he developed symptomatic hypocalcemia (albumin-adjusted serum calcium 7.4 mg/dL and phosphorus 5.1 mg/dL), requiring increased oral calcium doses to restore calcium levels to target ranges.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  7. 07HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation and conventional therapy adjustments, a man's calcium returned to therapeutic ranges.

    In plain wordsAfter palopegteriparatide discontinuation and conventional therapy adjustments, a man's calcium returned to therapeutic ranges.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableCalcium recovery after regimen adjustment
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    After dose adjustments, calcium and phosphorus levels returned to therapeutic ranges, with the patient reporting symptom improvement.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  8. 08HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation and conventional therapy adjustments, a man's phosphorus returned to therapeutic ranges.

    In plain wordsAfter palopegteriparatide discontinuation and conventional therapy adjustments, a man's phosphorus returned to therapeutic ranges.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicablePhosphorus recovery after regimen adjustment
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    After dose adjustments, calcium and phosphorus levels returned to therapeutic ranges, with the patient reporting symptom improvement.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  9. 09HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation and conventional therapy adjustments, a man reported symptom improvement.

    In plain wordsAfter palopegteriparatide discontinuation and conventional therapy adjustments, a man reported symptom improvement.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseSymptoms after regimen adjustment
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    After dose adjustments, calcium and phosphorus levels returned to therapeutic ranges, with the patient reporting symptom improvement.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  10. 10HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation and regimen adjustments, a man's calcium remained stable six months later.

    In plain wordsAfter palopegteriparatide discontinuation and regimen adjustments, a man's calcium remained stable six months later.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableLater calcium stability
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    Six months later, his calcium and phosphorus levels remained stable, and the dose of calcium and calcitriol therapy was lower than pre-treatment with palopegteriparatide.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  11. 11HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation and regimen adjustments, a man's phosphorus remained stable six months later.

    In plain wordsAfter palopegteriparatide discontinuation and regimen adjustments, a man's phosphorus remained stable six months later.

    Peptide
    Palopegteriparatide
    Outcome
    Not applicableLater phosphorus stability
    Study

    n = 1

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    Six months later, his calcium and phosphorus levels remained stable, and the dose of calcium and calcitriol therapy was lower than pre-treatment with palopegteriparatide.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  12. 12HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a man's calcium dose was lower than before palopegteriparatide six months later.

    In plain wordsAfter palopegteriparatide discontinuation, a man's calcium dose was lower than before palopegteriparatide six months later.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseLater calcium dose
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    Six months later, his calcium and phosphorus levels remained stable, and the dose of calcium and calcitriol therapy was lower than pre-treatment with palopegteriparatide.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment
  13. 13HumanCase report or seriesSafety outcome

    After palopegteriparatide discontinuation, a man's calcitriol dose was lower than before palopegteriparatide six months later.

    In plain wordsAfter palopegteriparatide discontinuation, a man's calcitriol dose was lower than before palopegteriparatide six months later.

    Peptide
    Palopegteriparatide
    Outcome
    DecreaseLater calcitriol dose
    Study

    n = 1

    Outcome group
    Conventional therapy requirements · Endocrine and hormones
    Studied dose
    Dose not stated · three yearsAs given in this study (human).

    Source sentences

    Summary
    Six months later, his calcium and phosphorus levels remained stable, and the dose of calcium and calcitriol therapy was lower than pre-treatment with palopegteriparatide.
    1 context sentence
    Summary · context
    We present the case of a 62-year-old male with postsurgical HypoPT who discontinued palopegteriparatide therapy after three years of treatment

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.